# reload+after+2024-01-23 17:48:08.692901
address1§2200 N. Commerce Parkway
address2§Suite 208
city§Weston
state§FL
zip§33326
country§United States
phone§754 231 1688
website§https://www.zyversa.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
fullTimeEmployees§7
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Stephen C. Glover', 'age': 63, 'title': 'Co-Founder, Chairman, CEO & President', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 450500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter  Wolfe', 'age': 55, 'title': 'CFO & Secretary', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 275000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen A. Cashmere', 'age': 71, 'title': 'Chief Commercial Officer', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 300000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Ms. Melda  Uzbil O'connell", 'title': 'Senior Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Pablo A. Guzman FACC, M.D.', 'age': 73, 'title': 'Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board', 'yearBorn': 1950, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-5.75
exchange§NGM
quoteType§EQUITY
shortName§ZyVersa Therapeutics, Inc.
longName§ZyVersa Therapeutics, Inc.
firstTradeDateEpochUtc§1644589800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§112f0bf3-c892-36d9-8e0c-2b96e360a307
gmtOffSetMilliseconds§-18000000
targetHighPrice§24.0
targetLowPrice§4.0
targetMeanPrice§14.0
targetMedianPrice§14.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§0.135
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
